| Literature DB >> 22056137 |
David A Brindley1, Brock C Reeve, William A Sahlman, Greg A Bonfiglio, Natasha L Davie, Emily J Culme-Seymour, Chris Mason.
Abstract
Stock market volatility in the cell therapy industry has greatly hindered the investment necessary to fund translational therapies. Here, we review the volatility of leading companies and suggest that a distinct industry is maturing to a point at which the volatility should subside, providing a more attractive environment for future growth. Copyright ÂMesh：
Year: 2011 PMID： 22056137 DOI： 10.1016/j.stem.2011.10.010
Source DB: PubMed Journal: Cell Stem Cell ISSN： 1875-9777 Impact factor: 24.633